Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia
- Michael F. Green,
Ph.D. , - Nina R. Schooler,
Ph.D. , - Robert S. Kern,
Ph.D. , - Fred J. Frese,
Ph.D. , - Wendy Granberry,
Pharm.D. , - Philip D. Harvey,
Ph.D. , - Craig N. Karson,
M.D. , - Nancy Peters,
R.N., M.B.A. , - Michelle Stewart,
Ph.D. , - Larry J. Seidman,
Ph.D. , - John Sonnenberg,
Ph.D. , - William S. Stone,
Ph.D. , - David Walling,
Ph.D. , - Ellen Stover,
Ph.D. , and - Stephen R. Marder,
M.D.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
From the Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles; VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; SUNY Downstate Medical Center, Brooklyn, N.Y.; VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore; Northeastern Ohio Universities College of Medicine, Rootstown; GlaxoSmithKline, Research Triangle Park, N.C.; Psychiatry and Behavioral Sciences, Emory University, Atlanta; Merck, North Wales, Pa.; Sanofi-Aventis, Malvern, Pa.; Pfizer, Inc., New London, Conn.; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston; Uptown Research Institute, Chicago; Collaborative Neuroscience Network, Garden Grove, Calif.; and NIMH, Bethesda, Md.
Supplemental Material
ajp_168_04_400_01.pdf (11 KB)